Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 11, 2014, Pages 1758-1766

  Reshef, Ran ^a   Hexner, Elizabeth O ^a   Loren, Alison W ^a   Frey, Noelle V ^a   Stadtmauer, Edward A ^a   Luger, Selina M ^a   Mangan, James K ^a   Gill, Saar I ^a   Vassilev, Pavel ^a   Lafferty, Kathryn A ^a   Smith, Jacqueline ^a   Van Deerlin, Vivianna M ^b   Mick, Rosemarie ^b   Porter, David L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Chimerism; Reduced intensity conditioning

Indexed keywords

BUSULFAN; FLUDARABINE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MORTALITY; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; SURVIVAL; T LYMPHOCYTE; ADVERSE EFFECTS; AGED; ALLOTRANSPLANTATION; DONOR; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; IMMUNOSUPPRESSIVE TREATMENT; MALE; MIDDLE AGED; PROCEDURES; RECURRENT DISEASE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RECURRENCE; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84908062984     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.07.003     Document Type: Article

References (54)

1. Porter D.L., Alyea E.P., Antin J.H., et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2010, 16:1467-1503.
2. Schmid C., Labopin M., Nagler A., et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood 2012, 119:1599-1606.
3. Storb R., Gyurkocza B., Storer B.E., et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. JClin Oncol 2013, 31:1530-1538.
4. Chen Y.B., Coughlin E., Kennedy K.F., et al. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia. Biol Blood Marrow Transplant 2013, 19:981-987.
5. Luger S.M., Ringden O., Zhang M.J., et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 2012, 47:203-211.
6. Brunstein C.G., Fuchs E.J., Carter S.L., et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011, 118:282-288.
7. Sureda A., Robinson S., Canals C., et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. JClin Oncol 2008, 26:455-462.
8. Gyurkocza B., Storb R., Storer B.E., et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. JClin Oncol 2010, 28:2859-2867.
9. Bethge W.A., Storer B.E., Maris M.B., et al. Relapse or progression afterhematopoietic cell transplantation using nonmyeloablative conditioning: effect of interventions on outcome. Exp Hematol 2003, 31:974-980.
10. Tauro S., Craddock C., Peggs K., et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. JClin Oncol 2005, 23:9387-9393.
11. Sureda A., Canals C., Arranz R., et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study-a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012, 97:310-317.
12. Antin J.H., Childs R., Filipovich A.H., et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2001, 7:473-485.
13. van Leeuwen J.E., van Tol M.J., Bodzinga B.G., et al. Detection of mixed chimaerism in flow-sorted cell subpopulations by PCR-amplified VNTR markers after allogeneic bone marrow transplantation. Br J Haematol 1991, 79:218-225.
14. + peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation. Haematologica 2009, 94:1613-1617.
15. Mackinnon S., Barnett L., Bourhis J.H., et al. Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA. Blood 1992, 80:3235-3241.
16. Dubovsky J., Daxberger H., Fritsch G., et al. Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection. Leukemia 1999, 13:2060-2069.
17. Frassoni F., Strada P., Sessarego M., et al. Mixed chimerism after allogeneic marrow transplantation for leukaemia: correlation with dose of total body irradiation and graft-versus-host disease. Bone Marrow Transplant 1990, 5:235-240.
18. van Leeuwen J.E., van Tol M.J., Joosten A.M., et al. Persistence of host-type hematopoiesis after allogeneic bone marrow transplantation for leukemia is significantly related to the recipient's age and/or the conditioning regimen, but it is not associated with an increased risk of relapse. Blood 1994, 83:3059-3067.
19. Valcarcel D., Martino R., Caballero D., et al. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2003, 31:387-392.
20. Baron F., Baker J.E., Storb R., et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004, 104:2254-2262.
21. Childs R., Clave E., Contentin N., et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999, 94:3234-3241.
22. Saito B., Fukuda T., Yokoyama H., et al. Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen. Biol Blood Marrow Transplant 2008, 14:1148-1155.
23. Armand P., Kim H.T., Logan B.R., et al. Validation and refinement of the disease risk index for allogeneic stem cell transplantation: a study from the CIBMTR. Blood 2014, 123:3664-3671.
24. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
25. Reshef R., Luger S.M., Hexner E.O., et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. NEngl J Med 2012, 367:135-145.
26. Van Deerlin V.M., Reshef R. Chimerism testing in allogeneic hematopoietic stem cell transplantation. Molecular pathology in clinical practice 2014, Springer, New York. 2nd ed. D.G. Leonard (Ed.).
27. Van Deerlin V.M., Leonard D.G. Bone marrow engraftment analysis after allogeneic bone marrow transplantation. Clin Lab Med 2000, 20:197-225.
28. Sutherland D.R., Anderson L., Keeney M., et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. JHematother 1996, 5:213-226.
29. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
30. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease. I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
31. Oran B., Giralt S., Couriel D., et al. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 2007, 21:2540-2544.
32. Craddock C., Nagra S., Peniket A., et al. Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 2010, 95:989-995.
33. Pollyea D.A., Artz A.S., Stock W., et al. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2007, 40:1027-1032.
34. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001, 97:3390-3400.
35. Matthes-Martin S., Lion T., Haas O.A., et al. Lineage-specific chimaerism after stem cell transplantation in children following reduced intensity conditioning: potential predictive value of NK cell chimaerism for late graft rejection. Leukemia 2003, 17:1934-1942.
36. Bornhauser M., Thiede C., Platzbecker U., et al. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin Cancer Res 2001, 7:2254-2262.
37. Mohty M., Avinens O., Faucher C., et al. Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. Haematologica 2007, 92:1004-1006.
38. van Besien K., Dew A., Lin S., et al. Patterns and kinetics of T-cell chimerism after allotransplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymph 2009, 50:1809-1817.
39. El-Cheikh J., Vazquez A., Crocchiolo R., et al. Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. Am J Hematol 2012, 87:1074-1078.
40. Rosenow F., Berkemeier A., Krug U., et al. CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT. Bone Marrow Transplant 2013, 48:1070-1076.
41. Lion T., Watzinger F., Preuner S., et al. The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation. Leukemia 2012, 26:1821-1828.
42. Paietta E. Minimal residual disease in acute myeloid leukemia: coming of age. Hematol Am Soc Hematol Educ Progr 2012, 2012:35-42.
43. Walter R.B., Buckley S.A., Pagel J.M., et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood 2013, 122:1813-1821.
44. Walter R.B., Gooley T.A., Wood B.L., et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. JClin Oncol 2011, 29:1190-1197.
45. Perez-Simon J.A., Caballero D., Diez-Campelo M., et al. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 2002, 16:1423-1431.
46. Gattinoni L., Finkelstein S.E., Klebanoff C.A., et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. JExp Med 2005, 202:907-912.
47. Salit R.B., Fowler D.H., Wilson W.H., et al. Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies. JClin Oncol 2012, 30:830-836.
48. Massenkeil G., Nagy M., Lawang M., et al. Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved. Bone Marrow Transplant 2003, 31:339-345.
49. Liga M., Triantafyllou E., Tiniakou M., et al. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen. Biol Blood Marrow Transplant 2013, 19:75-81.
50. Mapara M.Y., Sykes M. Induction of mixed vs full chimerism to potentiate GVL effects after bone-marrow transplantation. Methods Mol Med 2005, 109:469-474.
51. Platzbecker U., Wermke M., Radke J., et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012, 26:381-389.
52. de Lima M., Giralt S., Thall P.F., et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010, 116:5420-5431.
53. Metzelder S.K., Schroeder T., Finck A., et al. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia 2012, 26:2353-2359.
54. Sharma M., Ravandi F., Bayraktar U.D., et al. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant 2011, 17:1874-1877.